PL361389A1 - Skuteczne terapie przeciwnowotworowe - Google Patents

Skuteczne terapie przeciwnowotworowe

Info

Publication number
PL361389A1
PL361389A1 PL01361389A PL36138901A PL361389A1 PL 361389 A1 PL361389 A1 PL 361389A1 PL 01361389 A PL01361389 A PL 01361389A PL 36138901 A PL36138901 A PL 36138901A PL 361389 A1 PL361389 A1 PL 361389A1
Authority
PL
Poland
Prior art keywords
effective antitumour
antitumour treatments
treatments
effective
tumour
Prior art date
Application number
PL01361389A
Other languages
English (en)
Inventor
Naoto Takahashi
Steve Weitman
Maurizio D'incalci
Glynn Thomas Faircloth
Rafaella Giavazzi
Andreas Gescher
Original Assignee
Pharma Mar, S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27399908&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL361389(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar, S.A. filed Critical Pharma Mar, S.A.
Publication of PL361389A1 publication Critical patent/PL361389A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL01361389A 2000-11-06 2001-11-06 Skuteczne terapie przeciwnowotworowe PL361389A1 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24623300P 2000-11-06 2000-11-06
US24809500P 2000-11-13 2000-11-13
US34598201P 2001-10-19 2001-10-19
PCT/GB2001/004902 WO2002036135A2 (en) 2000-11-06 2001-11-06 Compositions for antitumour treatment containing ecteinascidin 743

Publications (1)

Publication Number Publication Date
PL361389A1 true PL361389A1 (pl) 2004-10-04

Family

ID=27399908

Family Applications (1)

Application Number Title Priority Date Filing Date
PL01361389A PL361389A1 (pl) 2000-11-06 2001-11-06 Skuteczne terapie przeciwnowotworowe

Country Status (24)

Country Link
US (3) US20040108086A1 (pl)
EP (1) EP1365808B1 (pl)
JP (2) JP4391083B2 (pl)
KR (1) KR100718946B1 (pl)
CN (1) CN100374162C (pl)
AT (1) ATE495793T1 (pl)
AU (2) AU2002212499B2 (pl)
BG (1) BG107843A (pl)
BR (1) BR0115162A (pl)
CA (1) CA2428160C (pl)
CY (1) CY1112361T1 (pl)
CZ (1) CZ20031327A3 (pl)
DE (1) DE60143911D1 (pl)
DK (1) DK1365808T3 (pl)
EA (1) EA005564B1 (pl)
HU (1) HUP0400648A3 (pl)
IL (1) IL155781A0 (pl)
MX (1) MXPA03003975A (pl)
NO (1) NO329981B1 (pl)
NZ (1) NZ525730A (pl)
PL (1) PL361389A1 (pl)
PT (1) PT1365808E (pl)
SK (1) SK287901B6 (pl)
WO (1) WO2002036135A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
PL368458A1 (pl) * 2001-10-19 2005-03-21 Pharmamar S.A. Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) * 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
US20100267732A1 (en) * 2007-10-19 2010-10-21 Pharma Mar, S.A. Prognostic Molecular Markers for ET-743 Treatment
RS54648B1 (sr) * 2010-11-12 2016-08-31 Pharma Mar S.A. Kombinovana terapija sa antitumorskim alkaloidom
GB201217439D0 (en) * 2012-09-28 2012-11-14 Topotarget As Combination therapy
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
KR102491180B1 (ko) 2017-04-27 2023-01-20 파르마 마르 에스.에이. 항종양 화합물
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
CN109276719A (zh) * 2018-11-01 2019-01-29 中山万汉制药有限公司 含有奥利司他纳米粒与蛋白激酶抑制剂的组合物
PE20252386A1 (es) 2019-11-21 2025-10-10 Pharma Mar Sa Metodo de tratamiento del cancer de pulmon de celulas pequenas con formulaciones de lurbinectedina
EP3960177A1 (en) * 2020-08-26 2022-03-02 Anturec Pharmaceuticals GmbH Composition comprising ttf-ngr for use in treating soft-tissue sarcoma

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja) * 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
BR9909488B1 (pt) * 1998-04-06 2011-02-08 ecteinascidinas semi-sintéticas e composição farmacêutica.
CA2331593C (en) * 1998-05-11 2008-08-05 Pharma Mar, S.A. Metabolites of ecteinascidin 743
JP2000081438A (ja) * 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
MXPA03007989A (es) * 2001-03-06 2003-12-04 Bristol Myers Squibb Co Metodo y forma de dosificacion para tratamiento de tumores por administracion de tegafur, uracil, acido folinico, paclitaxel y carboplatin.
JP4391038B2 (ja) * 2001-05-10 2009-12-24 パナソニック株式会社 電気炊飯器
PL368458A1 (pl) * 2001-10-19 2005-03-21 Pharmamar S.A. Zastosowanie związku przeciwrakowego przy ulepszonym harmonogramie dawkowania, do leczenia raka
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
HRP20080598T3 (en) * 2003-11-13 2009-01-31 Pharma Mar Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2004291037A1 (en) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Combination therapy comprising the use of ET-743 and paclitaxel for treating cancer
WO2006005602A2 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
AU2005288696A1 (en) * 2004-09-28 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
EP1827500B1 (en) * 2004-10-26 2009-05-06 Pharma Mar S.A., Sociedad Unipersonal Pegylated liposomal doxorubicin in combination with ecteinescidin 743
ATE368461T1 (de) * 2004-10-29 2007-08-15 Pharma Mar Sa Zusammensetzungen enthaltend ecteinascidin und einen disaccharide
ES2361566T3 (es) * 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
CA2652035A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments

Also Published As

Publication number Publication date
US20090324744A1 (en) 2009-12-31
AU2002212499B2 (en) 2006-11-02
BR0115162A (pt) 2003-10-21
BG107843A (bg) 2004-06-30
WO2002036135A2 (en) 2002-05-10
DE60143911D1 (de) 2011-03-03
JP4391083B2 (ja) 2009-12-24
CA2428160A1 (en) 2002-05-10
JP2009114212A (ja) 2009-05-28
US20040108086A1 (en) 2004-06-10
NZ525730A (en) 2004-12-24
NO20032027D0 (no) 2003-05-06
US20120107417A1 (en) 2012-05-03
KR20030048127A (ko) 2003-06-18
EP1365808B1 (en) 2011-01-19
ATE495793T1 (de) 2011-02-15
EA005564B1 (ru) 2005-04-28
MXPA03003975A (es) 2004-02-12
EA200300544A1 (ru) 2003-08-28
NO329981B1 (no) 2011-01-31
HK1060067A1 (en) 2004-07-30
CY1112361T1 (el) 2015-12-09
IL155781A0 (en) 2003-12-23
WO2002036135A3 (en) 2003-04-10
CZ20031327A3 (cs) 2003-11-12
NO20032027L (no) 2003-07-04
CN100374162C (zh) 2008-03-12
CA2428160C (en) 2009-10-13
AU1249902A (en) 2002-05-15
HUP0400648A3 (en) 2012-09-28
PT1365808E (pt) 2011-04-08
SK287901B6 (sk) 2012-03-02
CN1486193A (zh) 2004-03-31
HUP0400648A2 (hu) 2004-06-28
SK5492003A3 (en) 2004-03-02
KR100718946B1 (ko) 2007-05-16
JP2004517056A (ja) 2004-06-10
DK1365808T3 (da) 2011-05-16
EP1365808A2 (en) 2003-12-03

Similar Documents

Publication Publication Date Title
AU1249902A (en) Effective antitumour treatments
MY145590A (en) Phenylacetamides and their use as glucokinase modulators
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
NZ544472A (en) Compounds and therapeutical use thereof
GEP20063799B (en) Tropane derivatives useful in therapy
NZ517038A (en) Use of serotonin reuptake inihibitor in medicaments for treating sexual dysfunction
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
GB0020504D0 (en) Therapeutic method
AU2002332488A8 (en) R-bambuterol, its preparation and therapeutic uses
PT1030667E (pt) Utilizacao de mirtazapina para o fabrico de um medicamento para o tratamento de apenas do sono
HRP20090345T1 (en) Pegylated liposomal doxorubicin in combination with ecteinescidin 743
NZ528164A (en) Use of flumazenil to produce a medicament for the treatment of cocaine dependency
PL371741A1 (pl) Leczenie skojarzone ostrego zawału mięśnia sercowego
GEP201606538B (en) Preoperative treatment of post operative pain
MXPA04005269A (es) Uso de alcanoil-l-carnitina para el tratamiento de disfuncion erectil.
AU2001236529A1 (en) Combination therapy for cancer
IL159770A0 (en) Calcium salts with cytotoxic activity
AU2003281257A8 (en) A novel use of rapamycin and structural analogues thereof
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
MY136408A (en) Active substance combinations and therapies for treating abuse of alcohol
GB0208129D0 (en) Method of treatment
NZ516564A (en) Cancer therapy

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)
DISD Decisions on discontinuance of the proceedings of a derived patent or utility model

Ref document number: 392186